Key regions: Germany, India, United Kingdom, China, Canada
The Oncology Drugs market in Eastern Asia has been experiencing significant growth in recent years.
Customer preferences: The increasing incidence of cancer in the region has led to a growing demand for oncology drugs. Patients are seeking more advanced treatments and are willing to pay a premium for drugs that offer better efficacy and fewer side effects. Additionally, the aging population in many Eastern Asian countries has contributed to the rise in cancer cases, further driving demand for oncology drugs.
Trends in the market: Japan is the largest market for oncology drugs in Eastern Asia, with a high demand for both traditional chemotherapy drugs and newer targeted therapies. The market in China is also growing rapidly, driven by government initiatives to improve cancer treatment and access to drugs. In South Korea, there is a trend towards personalized medicine, with a focus on developing drugs that target specific genetic mutations. In Taiwan, there is a growing interest in immunotherapy drugs, which stimulate the body's immune system to fight cancer.
Local special circumstances: One of the unique features of the oncology drugs market in Eastern Asia is the prevalence of traditional Chinese medicine (TCM). Many patients in the region use TCM alongside Western medicine, and there is a growing interest in developing TCM-based oncology drugs. In addition, there are significant differences in pricing and reimbursement policies across the region, which can impact drug availability and affordability.
Underlying macroeconomic factors: The strong economic growth in many Eastern Asian countries has led to increased healthcare spending, which has contributed to the growth of the oncology drugs market. Additionally, the region has a highly skilled workforce and a strong research and development infrastructure, which has enabled the development of innovative new drugs. However, there are also challenges in the region, including regulatory barriers and intellectual property issues, which can impact drug development and availability.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
